TY  - JOUR
AU  - Dréno, Brigitte
AU  - Ascierto, Paolo A
AU  - Atkinson, Victoria
AU  - Liszkay, Gabriella
AU  - Maio, Michele
AU  - Mandalà, Mario
AU  - Demidov, Lev
AU  - Stroyakovskiy, Daniil
AU  - Thomas, Luc
AU  - de la Cruz-Merino, Luis
AU  - Dutriaux, Caroline
AU  - Garbe, Claus
AU  - Bartley, Karen
AU  - Karagiannis, Thomas
AU  - Chang, Ilsung
AU  - Rooney, Isabelle
AU  - Koralek, Daniel O
AU  - Larkin, James
AU  - McArthur, Grant A
AU  - Ribas, Antoni
PY  - 2018
DO  - 10.1038/bjc.2017.488
UR  - http://hdl.handle.net/10668/12124
T2  - British journal of cancer
AB  - In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis of health-related quality of life (HRQOL)...
LA  - en
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Azetidines
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Longitudinal Studies
KW  - Male
KW  - Melanoma
KW  - Mutation
KW  - Piperidines
KW  - Placebos
KW  - Proto-Oncogene Proteins B-raf
KW  - Quality of Life
KW  - Vemurafenib
TI  - Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.
TY  - research article
VL  - 118
ER  -